(Q43237391)

English

The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response

scientific article published on 20 November 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

W. Kimryn Rathmell

3

object named as

W Kimryn Rathmell

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

author name string

C Lance Cowey

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Julia R Fielding

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

language of work or name

0 references

publication date

20 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1108-13.e1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sunitinib efficacy against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

3-D imaging with MDCT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.105

7 January 2021

Identifiers

10.1016/J.UROLOGY.2009.06.105

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43237391&oldid=1984663714"